SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic
SGLT2抑制剂在MASLD（代谢功能障碍相关脂肪肝）中除了心血管代谢获益外，还具有持续的肝脏获益。
期刊:Pharmaceuticals
影响因子:4.8
doi:10.3390/ph18081118
Suki, Mohamad; Imam, Ashraf; Amer, Johnny; Milgrom, Yael; Massarwa, Muhammad; Hazou, Wadi; Tiram, Yariv; Perzon, Ofer; Sharif, Yousra; Sackran, Joseph; Alon, Revital; Lourie, Nachum; Hershko Klement, Anat; Shibli, Safa; Safadi, Tamer; Raz, Itamar; Khalaileh, Abed; Safadi, Rifaat
